ChemoCentryx Inc. (NASDAQ:CCXI) traded down 3.5% during mid-day trading on Wednesday . The company traded as low as $4.47 and last traded at $4.47, with a volume of 67,961 shares changing hands. The stock had previously closed at $4.63.

A number of equities research analysts recently issued reports on the stock. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 19th. Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Monday, May 16th.

The company’s market capitalization is $198.86 million. The firm has a 50-day moving average of $4.61 and a 200 day moving average of $3.76.

ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.07. On average, equities research analysts forecast that ChemoCentryx Inc. will post ($0.35) EPS for the current year.

In other news, Director Geoffrey M. Parker bought 40,000 shares of the business’s stock in a transaction that occurred on Friday, May 13th. The stock was purchased at an average price of $4.03 per share, with a total value of $161,200.00. Following the purchase, the director now owns 13,514 shares of the company’s stock, valued at approximately $54,461.42. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas A. Edwards bought 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 17th. The stock was purchased at an average cost of $4.05 per share, with a total value of $202,500.00. Following the purchase, the director now directly owns 91,977 shares in the company, valued at approximately $372,506.85. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in ChemoCentryx stock. Westfield Capital Management Co. LP increased its position in shares of ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned approximately 2.50% of ChemoCentryx worth $8,929,000 at the end of the most recent quarter.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.